Biotech and Pharma Industry News | BioPharma Dive
WEBCell and gene therapy investment, once booming, is now in a slump. Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Biotech M&A is on the upswing. Here are the latest deals.
WEBAug 13, 2024 · Even neuroscience, which large drugmakers previously abandoned, is drawing investment again. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Click on an acquiring …
A decade later, biotech’s CRISPR revolution is still going strong
WEBOct 11, 2023 · A cell and an injection needle are projected onto a screen during a CRISPR/Cas9 experiment in Berlin, Germany, on May 22, 2018. A research paper published a decade ago touched off a biomedical revolution that has made careers, spawned companies and drawn billions of dollars of investment. By the end of the year, …
Chasing Novo and Lilly: The obesity drugs that could challenge …
WEBApr 30, 2024 · One study can start a pharmaceutical revolution. Four years ago, a large clinical trial run by Novo Nordisk showed a drug called semaglutide helped people with obesity lose, on average, around 15% of their weight.The results far exceeded what prior studies of other treatments had suggested was possible pharmaceutically, sparking a …
J&J's new cancer drug leads a growing pipeline of dual-targeting ...
WEBMay 24, 2021 · The Food and Drug Administration's approval of Johnson & Johnson's Rybrevant on Friday marked only the third time a drug of its type has won regulatory clearance in the U.S., and just the second time to treat cancer.. Behind Rybrevant, though, is a growing pipeline of so-called bispecific antibodies, offering hope that physicians may …
FDA lifts hold on Bluebird’s sickle cell gene therapy
WEBDec 19, 2022 · Dive Brief: Bluebird bio can resume enrolling and treating children and adolescents with sickle cell disease after the Food and Drug Administration lifted a clinical hold on the biotechnology company’s gene therapy for the blood disorder. The agency had imposed the partial study suspension in December 2021 after one trial participant ...
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
WEBMay 10, 2022 · Pfizer has agreed to acquire Biohaven Pharmaceuticals for $11.6 billion in a deal that turns an existing alliance on a fast-selling migraine drug into a big bet on its future growth. Pfizer will pay $148.50 per share in cash for each Biohaven share it doesn’t already own, representing a roughly 79% premium to the company’s Monday closing ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB5 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high …